IDEAS home Printed from https://ideas.repec.org/r/sae/medema/v20y2000i3p332-342.html
   My bibliography  Save this item

Willingness to Pay for a Quality-adjusted Life Year

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Dorothea Kesztyüs & Romy Lauer & Anja Schreiber & Tibor Kesztyüs & Reinhold Kilian & Jürgen Steinacker, 2014. "Parents’ willingness to pay for the prevention of childhood overweight and obesity," Health Economics Review, Springer, vol. 4(1), pages 1-8, December.
  2. Hunt Allcott & Benjamin B Lockwood & Dmitry Taubinsky, 2019. "Regressive Sin Taxes, with an Application to the Optimal Soda Tax," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 134(3), pages 1557-1626.
  3. Pinto-Prades, Jose Luis & Loomes, Graham & Brey, Raul, 2009. "Trying to estimate a monetary value for the QALY," Journal of Health Economics, Elsevier, vol. 28(3), pages 553-562, May.
  4. Amaia Malet-Larrea & Estíbaliz Goyenechea & Miguel A. Gastelurrutia & Begoña Calvo & Victoria García-Cárdenas & Juan M. Cabases & Aránzazu Noain & Fernando Martínez-Martínez & Daniel Sabater-Hernández, 2017. "Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(9), pages 1069-1078, December.
  5. Cam Donaldson & Helen Mason & Phil Shackley, 2012. "Contingent Valuation in Health Care," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 40, Edward Elgar Publishing.
  6. James K. Hammitt, 2017. "Valuing Non-Fatal Health Risks: Monetary and Health-Utility Measures," Revue économique, Presses de Sciences-Po, vol. 68(3), pages 335-356.
  7. Matthew Calver, 2016. "Measuring the Appropriate Outcomes for Better Decision-Making: A Framework to Guide the Analysis of Health Policy," CSLS Research Reports 2016-03, Centre for the Study of Living Standards.
  8. Amirabbas Mofidi & Emile Tompa & Christina Kalcevich & Christopher McLeod & Martin Lebeau & Chaojie Song & Joanne Kim & Paul A. Demers, 2022. "Occupational Exposure to Wood Dust and the Burden of Nasopharynx and Sinonasal Cancer in Canada," IJERPH, MDPI, vol. 19(3), pages 1-16, January.
  9. Jun Li & Benjamin H K Yip & Chichiu Leung & Wankyo Chung & Kin On Kwok & Emily Y Y Chan & Engkiong Yeoh & Puihong Chung, 2018. "Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-18, January.
  10. James P Moriarty & Bijan J Borah & Robert L Foote & Jose S Pulido & Nilay D Shah, 2015. "Cost-Effectiveness of Proton Beam Therapy for Intraocular Melanoma," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-14, May.
  11. Li, Y. & Zhu, M. & Klein, R. & Kong, N., 2014. "Using a partially observable Markov chain model to assess colonoscopy screening strategies – A cohort study," European Journal of Operational Research, Elsevier, vol. 238(1), pages 313-326.
  12. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
  13. Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
  14. Clément Carbonnier, 2023. "Welfare Economics and Neoliberalism: Interpreting the ideal type of perfect competition general equilibrium," Working Papers hal-04062786, HAL.
  15. Benjamin Ho & Sita N. Slavov, 2012. "An alternative perspective on health inequality," Economics Bulletin, AccessEcon, vol. 32(4), pages 3182-3196.
  16. Jacopo Garlasco & Mario Cesare Nurchis & Valerio Bordino & Martina Sapienza & Gerardo Altamura & Gianfranco Damiani & Maria Michela Gianino, 2022. "Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis," IJERPH, MDPI, vol. 19(8), pages 1-17, April.
  17. Stein, Alexander J., 2013. "Rethinking the measurement of undernutrition in a broader health context: Should we look at possible causes or actual effects," IFPRI discussion papers 1298, International Food Policy Research Institute (IFPRI).
  18. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
  19. Jonathan Skinner & Douglas Staiger, 2015. "Technology Diffusion and Productivity Growth in Health Care," The Review of Economics and Statistics, MIT Press, vol. 97(5), pages 951-964, December.
  20. Katherine Stackelberg & James Hammitt, 2009. "Use of Contingent Valuation to Elicit Willingness-to-Pay for the Benefits of Developmental Health Risk Reductions," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 43(1), pages 45-61, May.
  21. Michael Jones-Lee & Susan Chilton & Hugh Metcalf & Jytte Nielsen, 2015. "Valuing gains in life expectancy: Clarifying some ambiguities," Journal of Risk and Uncertainty, Springer, vol. 51(1), pages 1-21, August.
  22. James Hammitt, 2013. "Admissible utility functions for health, longevity, and wealth: integrating monetary and life-year measures," Journal of Risk and Uncertainty, Springer, vol. 47(3), pages 311-325, December.
  23. Marilyn S. Nanney & Samuel L. Myers & Man Xu & Kateryna Kent & Thomas Durfee & Michele L. Allen, 2019. "The Economic Benefits of Reducing Racial Disparities in Health: The Case of Minnesota," IJERPH, MDPI, vol. 16(5), pages 1-13, March.
  24. Reza Yaesoubi & Stephen Roberts, 2010. "A game-theoretic framework for estimating a health purchaser’s willingness-to-pay for health and for expansion," Health Care Management Science, Springer, vol. 13(4), pages 358-377, December.
  25. David Bardey & Philippe de Donder & Vera Zaporozhets, 2024. "The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests - A Literature Review," Working Papers hal-04472485, HAL.
  26. Dorte Gyrd‐Hansen, 2003. "Willingness to pay for a QALY," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1049-1060, December.
  27. Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy, 2010. "Terminal Care and The Value of Life Near Its End," NBER Working Papers 15649, National Bureau of Economic Research, Inc.
  28. Howard, David H., 2005. "Life expectancy and the value of early detection," Journal of Health Economics, Elsevier, vol. 24(5), pages 891-906, September.
  29. Smith, Richard D. & Richardson, Jeff, 2005. "Can we estimate the `social' value of a QALY?: Four core issues to resolve," Health Policy, Elsevier, vol. 74(1), pages 77-84, September.
  30. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
  31. Zarko Kalamov, 2021. "Evaluating Marginal Internalities: A New Approach," CESifo Working Paper Series 9476, CESifo.
  32. Scott Johnson & Matthew Davis & Anna Kaltenboeck & Howard Birnbaum & ElizaBeth Grubb & Marcy Tarrants & Andrew Siderowf, 2011. "Early retirement and income loss in patients with early and advanced Parkinson’s disease," Applied Health Economics and Health Policy, Springer, vol. 9(6), pages 367-376, November.
  33. Frank Lichtenberg, 2015. "The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 339-359, September.
  34. Brian Mills & Dan Unrau & Laurel Pentelow & Kelsey Spring, 2010. "Assessment of lightning-related damage and disruption in Canada," Natural Hazards: Journal of the International Society for the Prevention and Mitigation of Natural Hazards, Springer;International Society for the Prevention and Mitigation of Natural Hazards, vol. 52(2), pages 481-499, February.
  35. Khachapon Nimdet & Nathorn Chaiyakunapruk & Kittaya Vichansavakul & Surachat Ngorsuraches, 2015. "A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-16, April.
  36. S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson, 2019. "Value of a QALY and VSI estimated with the chained approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 1063-1077, September.
  37. Michael Kattan & Stephanie Earnshaw & Cheryl McDade & Libby Black & Gerald Andriole, 2011. "Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 305-315, September.
  38. Hoy, Michael & Polborn, Mattias K., 2015. "The value of technology improvements in games with externalities: A fresh look at offsetting behavior," Journal of Public Economics, Elsevier, vol. 131(C), pages 12-20.
  39. Kevin Haninger & James K. Hammitt, 2011. "Diminishing Willingness to Pay per Quality‐Adjusted Life Year: Valuing Acute Foodborne Illness," Risk Analysis, John Wiley & Sons, vol. 31(9), pages 1363-1380, September.
  40. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
  41. Mulligan, Karen & Baid, Drishti & Doctor, Jason N. & Phelps, Charles E. & Lakdawalla, Darius N., 2024. "Risk preferences over health: Empirical estimates and implications for medical decision-making," Journal of Health Economics, Elsevier, vol. 94(C).
  42. Lakdawalla, Darius N. & Phelps, Charles E., 2020. "Health technology assessment with risk aversion in health," Journal of Health Economics, Elsevier, vol. 72(C).
  43. Richard H. Chapman & Marc Berger & Milton C. Weinstein & Jane C. Weeks & Sue Goldie & Peter J. Neumann, 2004. "When does quality‐adjusting life‐years matter in cost‐effectiveness analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 429-436, May.
  44. Daniel Bauer & Darius Lakdawalla & Julian Reif, 2018. "Mortality Risk, Insurance, and the Value of Life," NBER Working Papers 25055, National Bureau of Economic Research, Inc.
  45. Hui Zhang & Christian Wernz & Danny R. Hughes, 2018. "Modeling and designing health care payment innovations for medical imaging," Health Care Management Science, Springer, vol. 21(1), pages 37-51, March.
  46. Tatia Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus, 2010. "Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder," PharmacoEconomics, Springer, vol. 28(9), pages 751-764, September.
  47. Sood Neeraj & Philipson Tomas J. & Huckfeldt Peter, 2013. "Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors," Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 101-122, April.
  48. Stephanie Earnshaw & Jonathan Graham & MerriKay Oleen-Burkey & Jane Castelli-Haley & Kenneth Johnson, 2009. "Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis," Applied Health Economics and Health Policy, Springer, vol. 7(2), pages 91-108, June.
  49. Patti Curl & Igor Vujic & Laura J van ‘t Veer & Susana Ortiz-Urda & James G Kahn, 2014. "Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma," PLOS ONE, Public Library of Science, vol. 9(9), pages 1-9, September.
  50. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
  51. Benjamin B. Lockwood & Dmitry Taubinsky, 2017. "Regressive Sin Taxes," NBER Working Papers 23085, National Bureau of Economic Research, Inc.
  52. James K. Hammitt, 2023. "Consistent valuation of a reduction in mortality risk using values per life, life year, and quality‐adjusted life year," Health Economics, John Wiley & Sons, Ltd., vol. 32(9), pages 1964-1981, September.
  53. Lichtenberg Frank R., 2017. "The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012," Forum for Health Economics & Policy, De Gruyter, vol. 20(1), pages 1-28, June.
  54. James K. Hammitt & Tuba Tunçel, 2023. "Monetary values of increasing life expectancy: Sensitivity to shifts of the survival curve," Journal of Risk and Uncertainty, Springer, vol. 67(3), pages 239-269, December.
  55. Donald S Shepard & Yara A Halasa & Dina M Fonseca & Ary Farajollahi & Sean P Healy & Randy Gaugler & Kristen Bartlett-Healy & Daniel A Strickman & Gary G Clark, 2014. "Economic Evaluation of an Area-Wide Integrated Pest Management Program to Control the Asian Tiger Mosquito in New Jersey," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-11, October.
  56. Robinson Lisa A. & Hammitt James K., 2013. "Skills of the trade: valuing health risk reductions in benefit-cost analysis," Journal of Benefit-Cost Analysis, De Gruyter, vol. 4(1), pages 107-130, March.
  57. Kittiphong Thiboonboon & Wantanee Kulpeng & Yot Teerawattananon, 2018. "An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities," PLOS ONE, Public Library of Science, vol. 13(6), pages 1-14, June.
  58. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.
  59. Tracy Lieu & G. Ray & Ismael Ortega-Sanchez & Ken Kleinman & Donna Rusinak, 2009. "Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster," PharmacoEconomics, Springer, vol. 27(12), pages 1005-1016, December.
  60. Tilling, C & Krol, M & Tsuchiya, A & Brazier, J & van Exel, J & Brouwer, W, 2009. "Measuring the value of life: exploring a new method for deriving the monetary value of a QALY," MPRA Paper 29911, University Library of Munich, Germany.
  61. Hammitt, James K. & Haninger, Kevin, 2017. "Valuing nonfatal health risk as a function of illness severity and duration: Benefit transfer using QALYs," Journal of Environmental Economics and Management, Elsevier, vol. 82(C), pages 17-38.
  62. Coskeran, Thomas & Denman, Antony & Phillips, Paul & Tornberg, Roger, 2007. "The cost-effectiveness of radon-proof membranes in new homes: A case study from Brixworth, Northamptonshire, UK," Health Policy, Elsevier, vol. 81(2-3), pages 195-206, May.
  63. Helen Mason & Michael Jones‐Lee & Cam Donaldson, 2009. "Modelling the monetary value of a QALY: a new approach based on UK data," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 933-950, August.
  64. Svensson, Mikael & Hultkrantz, Lars, 2012. "The Willingness to Pay for a QALY - Results based on value of statistical life estimates in Sweden," Karlstad University Working Papers in Economics 2, Karlstad University, Department of Economics.
  65. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
  66. Frank R. Lichtenberg, 2017. "How Cost-Effective Are New Cancer Drugs in the U.S.?," CESifo Working Paper Series 6683, CESifo Group Munich.
  67. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
  68. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "In sickness but not in wealth: Field evidence on patients’ risk preferences in the financial and health domain," Working Papers 31053, Imperial College, London, Imperial College Business School.
  69. Ivar Kristiansen & Kerstin Bingefors & Dag Nyholm & Dag Isacson, 2009. "Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 167-180, September.
  70. Frank R. Lichtenberg, 2017. "The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013," Latin American Economic Review, Springer;Centro de Investigaciòn y Docencia Económica (CIDE), vol. 26(1), pages 1-22, December.
  71. Son Nghiem & Nicholas Graves & Adrian Barnett & Catherine Haden, 2017. "Cost-effectiveness of national health insurance programs in high-income countries: A systematic review," PLOS ONE, Public Library of Science, vol. 12(12), pages 1-11, December.
  72. Zethraeus, Niklas & Borgström, Fredrik & Jönsson, Bengt & Kanis, John, 2004. "A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden – results based on the Women’s Health Initiative randomised controlled trial," SSE/EFI Working Paper Series in Economics and Finance 571, Stockholm School of Economics.
  73. Taehwan Park & Hyemin Kim & Seunghyun Song & Scott K. Griggs, 2022. "Economic Evaluation of Pharmacist-Led Digital Health Interventions: A Systematic Review," IJERPH, MDPI, vol. 19(19), pages 1-16, September.
  74. Lars Hein & Pete Roberts & Lucia Gonzalez, 2016. "Valuing a Statistical Life Year in Relation to Clean Air," Journal of Environmental Assessment Policy and Management (JEAPM), World Scientific Publishing Co. Pte. Ltd., vol. 18(04), pages 1-24, December.
  75. Ted R Miller & Geetha M Waehrer & Debora L Oh & Sukhdip Purewal Boparai & Sheila Ohlsson Walker & Sara Silverio Marques & Nadine Burke Harris, 2020. "Adult health burden and costs in California during 2013 associated with prior adverse childhood experiences," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-15, January.
  76. Nicolas Boespflug & Jérôme Wittwer & Antoine Bénard, 2024. "Factors associated with the author-reported cost-effectiveness threshold in high-income countries: systematic review and multivariable modelling," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(4), pages 631-639, June.
  77. Stephanie Earnshaw & Cheryl McDade & Libby Black & Christopher Bell & Michael Kattan, 2010. "Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations," PharmacoEconomics, Springer, vol. 28(6), pages 489-505, June.
  78. Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
  79. repec:imp:wpaper:12579 is not listed on IDEAS
  80. Marion S. Rauner & Walter J. Gutjahr & Kurt Heidenberger & Joachim Wagner & Joseph Pasia, 2010. "Dynamic Policy Modeling for Chronic Diseases: Metaheuristic-Based Identification of Pareto-Optimal Screening Strategies," Operations Research, INFORMS, vol. 58(5), pages 1269-1286, October.
  81. Weidema, Bo Pedersen, 2009. "Using the budget constraint to monetarise impact assessment results," Ecological Economics, Elsevier, vol. 68(6), pages 1591-1598, April.
  82. Franz Hessel & Christoph Wegner & Johannes Müller & Christina Glaveris & Jürgen Wasem, 2004. "Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(1), pages 58-63, February.
  83. Herrera-Araujo, Daniel & Hammitt, James K. & Rheinberger, Christoph M., 2020. "Theoretical bounds on the value of improved health," Journal of Health Economics, Elsevier, vol. 72(C).
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.